John D. Young
Net Worth
Last updated:
What is John D. Young net worth?
The estimated net worth of Mr. John D. Young is at least $46,534,182 as of 11 Nov 2021. He owns shares worth $10,268,382 as insider, has earned $15,025,800 from insider trading and has received compensation worth at least $21,240,000 in Pfizer Inc..
What is the salary of John D. Young?
Mr. John D. Young salary is $3,540,000 per year as Advisor in Pfizer Inc..
How old is John D. Young?
Mr. John D. Young is 60 years old, born in 1965.
What stocks does John D. Young currently own?
As insider, Mr. John D. Young owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Pfizer Inc. (PFE) | Advisor | 406,186 | $25.28 | $10,268,382 |
What does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
John D. Young insider trading
Pfizer Inc.
Mr. John D. Young has made 2 insider trades between 2019-2021, according to the Form 4 filled with the SEC. Most recently he sold 150,000 units of PFE stock worth $7,512,900 on 11 Nov 2021.
The largest trade he's ever made was exercising 163,334 units of PFE stock on 25 Feb 2021. As of 11 Nov 2021 he still owns at least 406,186 units of PFE stock.
Pfizer key executives
Pfizer Inc. executives and other stock owners filed with the SEC:
- Dr. Albert Bourla D.V.M., DVM, Ph.D. (63) Chairman & Chief Executive Officer
- Dr. Mikael Dolsten M.D., Ph.D. (67) Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical
- Mr. John D. Young (60) Advisor
- Ms. Angela Hwang (59) Group Pres of Biopharmaceuticals Group